FDA Approves Exkivity for Advanced NSCLC with EGFR Exon 20 Insertion Mutation
On September 15th, 2021, the Food and Drug Administration (FDA) approved Exkivity (mobocertinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in EGFR called exon 20 insertion. The FDA based their approval on the results [...]